DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.1%) at 15,256 as of Monday, June 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,353 issues advancing vs. 1,578 declining with 107 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Catamaran ( CTRX), down 4.00, Regeneron Pharmaceuticals ( REGN), down 2.14, Smith & Nephew ( SNN), down 1.61, Celgene Corporation ( CELG), down 1.16 and Biogen Idec ( BIIB), down 1.25. Top gainers within the sector include ACADIA Pharmaceuticals ( ACAD), up 15.9%, UnitedHealth Group ( UNH), up 2.0%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.7%, Teva Pharmaceutical Industries ( TEVA), up 1.4% and Aetna ( AET), up 1.1%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Dynavax Technologies Corporation ( DVAX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Dynavax Technologies Corporation is down $0.88 (-35.4%) to $1.60 on heavy volume Thus far, 13.5 million shares of Dynavax Technologies Corporation exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $1.58-$1.84 after having opened the day at $1.82 as compared to the previous trading day's close of $2.47.

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Dynavax Technologies Corporation has a market cap of $466.4 million and is part of the drugs industry. Shares are down 10.5% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Dynavax Technologies Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Dynavax Technologies Corporation as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Dynavax Technologies Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Dr. Reddy Laboratories ( RDY) is down $0.96 (-2.5%) to $37.74 on light volume Thus far, 60,409 shares of Dr. Reddy Laboratories exchanged hands as compared to its average daily volume of 233,900 shares. The stock has ranged in price between $37.61-$37.98 after having opened the day at $37.93 as compared to the previous trading day's close of $38.70.

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr. Reddy Laboratories has a market cap of $6.4 billion and is part of the drugs industry. The company has a P/E ratio of 23.0, above the S&P 500 P/E ratio of 17.7. Shares are up 16.3% year to date as of the close of trading on Friday. Currently there is 1 analyst that rates Dr. Reddy Laboratories a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Dr. Reddy Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Dr. Reddy Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Onyx Pharmaceuticals ( ONXX) is down $2.00 (-2.2%) to $90.30 on light volume Thus far, 221,158 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $90.00-$92.97 after having opened the day at $92.30 as compared to the previous trading day's close of $92.30.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $6.6 billion and is part of the drugs industry. Shares are up 20.2% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full Onyx Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $1.57 (-1.7%) to $92.81 on average volume Thus far, 696,286 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $91.55-$94.66 after having opened the day at $94.66 as compared to the previous trading day's close of $94.38.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.1 billion and is part of the drugs industry. The company has a P/E ratio of 63.6, above the S&P 500 P/E ratio of 17.7. Shares are down 0.9% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $0.45 (-0.5%) to $85.14 on light volume Thus far, 576,825 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $84.34-$86.05 after having opened the day at $85.89 as compared to the previous trading day's close of $85.59.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $25.8 billion and is part of the drugs industry. Shares are up 43.2% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing